Novo Nordisk's Oral Wegovy Hits Record 20,371 Prescriptions in Second Week, Nearly 500% Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2026
0mins
Source: Benzinga
- Prescription Surge: Novo Nordisk's oral Wegovy reached 20,371 prescriptions in its second week, a nearly 500% increase from 4,289 in the first week, indicating rapid market acceptance that could reshape revenue trajectories in the weight-loss drug market.
- Significant Market Potential: This figure is likely conservative as retail prescription data excludes Novo Nordisk's direct-to-consumer channels and telehealth platforms, suggesting actual demand could be double or triple the reported number, indicating a larger market opportunity.
- Clear Competitive Advantage: With distribution in over 70,000 retail locations, Novo Nordisk has established brand loyalty before Eli Lilly's oral competitor, Orforglipron, is set to launch in 2026, giving Novo a significant first-mover advantage.
- Industry Transformation Signal: The mainstream adoption of oral GLP-1 drugs could dramatically expand the total addressable market for weight-loss medications, altering revenue trajectories for both Novo and Lilly, with increasing market attention suggesting Wall Street may be underestimating the potential explosion in this sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Novo Nordisk Cuts GLP-1 Drug Prices in India Amid Competition
- Price Reduction: Novo Nordisk has lowered the prices of Ozempic and Wegovy in India to ₹1,415 ($15.04) for the lowest doses, down from ₹2,200 and ₹2,712, representing reductions of 23.8% and 27% respectively, aimed at countering competition from local generics.
- Increased Market Competition: Following the expiration of a key patent on March 20, at least six local pharmaceutical companies have launched off-patent versions of semaglutide, forcing Novo Nordisk to adopt a pricing strategy to maintain its market share.
- Profit Forecast Downgrade: In February, Novo Nordisk projected a potential 13% decline in profits for 2023 due to patent expirations, indicating ongoing pressure from generics that could impact its profitability.
- Response to Patient Feedback: Vikrant Shrotriya, managing director of Novo Nordisk India, stated that the company is acting on feedback from patients and doctors, demonstrating its sensitivity and adaptability to market demands.
See More
Stock Index Futures Rise as Investors Eye Four Key Companies
- Nike Earnings Focus: Nike (NKE) is set to report its fiscal third-quarter results after the market closes, with analysts expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year's $0.54, prompting investors to closely monitor demand trends in China and margin outlook amid new challenges.
- Novo Nordisk Subscription Program: Novo Nordisk (NVO) slipped 0.14% in premarket trading after announcing a first-of-its-kind subscription program for its weight loss therapy Wegovy, allowing cash-paying patients to choose 3-, 6-, or 12-month subscriptions starting March 31, with longer terms offering lower monthly prices.
- Marvell Technology Surge: Marvell Technology (MRVL) jumped over 10% in premarket trading following Nvidia's announcement of a $2 billion investment and a strategic partnership to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem, enhancing its market position in AI technologies.
- Eli Lilly Acquires Centessa: Eli Lilly (LLY) gained 0.86% before the opening bell after announcing a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, which will bolster Lilly's portfolio in treating excessive daytime sleepiness and other neurological conditions.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Novo Nordisk Cuts GLP-1 Drug Prices in India Amid Competition
- Price Reduction: Novo Nordisk has lowered the prices of Ozempic and Wegovy in India to ₹1,415 ($15.04) for the lowest doses, down from ₹2,200 and ₹2,712, representing reductions of 23.8% and 27% respectively, aimed at countering competition from local generics.
- Increased Market Competition: Following the expiration of a key patent on March 20, at least six local pharmaceutical companies have launched off-patent versions of semaglutide, forcing Novo Nordisk to adopt a pricing strategy to maintain its market share.
- Profit Forecast Downgrade: In February, Novo Nordisk projected a potential 13% decline in profits for 2023 due to patent expirations, indicating ongoing pressure from generics that could impact its profitability.
- Response to Patient Feedback: Vikrant Shrotriya, managing director of Novo Nordisk India, stated that the company is acting on feedback from patients and doctors, demonstrating its sensitivity and adaptability to market demands.
See More
Stock Index Futures Rise as Investors Eye Four Key Companies
- Nike Earnings Focus: Nike (NKE) is set to report its fiscal third-quarter results after the market closes, with analysts expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year's $0.54, prompting investors to closely monitor demand trends in China and margin outlook amid new challenges.
- Novo Nordisk Subscription Program: Novo Nordisk (NVO) slipped 0.14% in premarket trading after announcing a first-of-its-kind subscription program for its weight loss therapy Wegovy, allowing cash-paying patients to choose 3-, 6-, or 12-month subscriptions starting March 31, with longer terms offering lower monthly prices.
- Marvell Technology Surge: Marvell Technology (MRVL) jumped over 10% in premarket trading following Nvidia's announcement of a $2 billion investment and a strategic partnership to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem, enhancing its market position in AI technologies.
- Eli Lilly Acquires Centessa: Eli Lilly (LLY) gained 0.86% before the opening bell after announcing a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, which will bolster Lilly's portfolio in treating excessive daytime sleepiness and other neurological conditions.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
